New smart oxygen device aims to free lung patients from constant monitoring
NCT ID NCT07222592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a lightweight, battery-powered device called MoblO2 that automatically adjusts oxygen flow to keep blood oxygen at a healthy level during exercise. It is designed for people with COPD or interstitial lung disease who need supplemental oxygen. Over two weeks, 48 participants will use the device while doing daily activities to see if it improves physical activity, oxygen use, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MoblO2 device (closed-loop oxygen delivery system)
What this could lead to
If it works, this device could make oxygen therapy easier and less burdensome, helping people with lung disease stay active and worry less about their oxygen levels.
What could go wrong
This is a small, early-stage study (48 people) testing a device for two weeks. It may not show clear benefits, and the device could malfunction or be inconvenient in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Stanford, California, 94305, United States